Fig. 2.

Mutational load is associated with benefit from ACT in melanoma. a Tumor mutational load by clinical response according to RECIST. P-value from Kruskal–Wallis test. Solid black line indicates the median. b Mutational load by clinical benefit groups, as defined in Methods section. P-value from Mann–Whitney test. c Tumor mutational load is significantly associated with progression-free survival, when the cohort in divided into three groups by mutational load. P-value from Cox regression. d Tumor mutational load is significantly associated with overall survival, when the cohort in divided into three groups by mutational load. P-value from Cox regression. RECIST categories: CR complete response; PD progressive disease; PR partial response; SD stable disease